ERBB2 and breast carcinoma: However, the treatment of HER2-amplified breast cancers has not followed this paradigm, and HER2-targeting kinase inhibitors have minimal or modest activities by themselves (Blackwell et al., 2010; Burstein et al., 2008; Martin et al., 2013; Swaby et al., 2009).